Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia

Journal of Experimental Medicine

Volumn 210, Issue 6, 2013, Pages 1065-1068

  Tran, Eric ^a   Chinnasamy, Dhanalakshmi ^a   Yu, Zhiya ^a   Morgan, Richard A ^a   Lee, Chyi Chia Richard ^b   Restifo, Nicholas P ^a   Rosenberg, Steven A ^a  

^a Surgery Branch   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; FIBROBLAST ACTIVATION PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN; SCA 1 ANTIGEN; UNCLASSIFIED DRUG; GELATINASE; LY ANTIGEN; MEMBRANE PROTEIN; SEPRASE; SERINE PROTEINASE; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE DISEASE; BONE MARROW CELL; CACHEXIA; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; GENETIC ENGINEERING; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MOUSE STRAIN; MULTIPOTENT STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; T LYMPHOCYTE; ANIMAL; BAGG ALBINO MOUSE; EXPERIMENTAL MELANOMA; FIBROBLAST; IMMUNOLOGY; MESENCHYMAL STROMA CELL; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIGENS, LY; ANTIGENS, NEOPLASM; CACHEXIA; CELL LINE, TUMOR; FEMALE; FIBROBLASTS; GELATINASES; HUMANS; MALE; MELANOMA, EXPERIMENTAL; MEMBRANE PROTEINS; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED BALB C; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTORS, ANTIGEN; SERINE ENDOPEPTIDASES; T-LYMPHOCYTES;

EID: 84880656055     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20130110     Document Type: Article

References (30)

1. Bae, S., C.W. Park, H.K. Son, H.K. Ju, D. Paik, C.J. Jeon, G.Y. Koh, J. Kim, and H. Kim. 2008. Fibroblast activation protein alpha identifies mesenchymal stromal cells from human bone marrow. Br. J. Haematol. 142:827-830. http://dx.doi.org/10.1111/j.1365-2141.2008.07241.x
2. da Silva Meirelles, L., P.C. Chagastelles, and N.B. Nardi. 2006. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J. Cell Sci. 119:2204-2213. http://dx.doi.org/10.1242/jcs.02932
3. Ding, L., T.L. Saunders, G. Enikolopov, and S.J. Morrison. 2012. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature. 481: 457-462. http://dx.doi.org/10.1038/nature10783
4. Dotti, G., B. Savoldo, and M. Brenner. 2009. Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum. Gene Ther. 20:1229-1239. http://dx.doi.org/10.1089/hum.2009.142
5. Eager, R.M., C.C. Cunningham, N. Senzer, D.A. Richards, R.N. Raju, B. Jones, M. Uprichard, and J. Nemunaitis. 2009a. Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer. Clin. Oncol. (R Coll Radiol). 21:464-472. http://dx.doi.org/10.1016/j.clon.2009.04.007
6. Eager, R.M., C.C. Cunningham, N.N. Senzer, J. Stephenson Jr., S.P. Anthony, S.J. O'Day, G. Frenette, A.C. Pavlick, B. Jones, M. Uprichard, and J. Nemunaitis. 2009b. Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma. BMC Cancer. 9:263. http://dx.doi.org/10.1186/1471-2407-9-263
7. Feig, C., A. Gopinathan, A. Neesse, D.S. Chan, N. Cook, and D.A. Tuveson. 2012. The pancreas cancer microenvironment. Clin. Cancer Res. 18: 4266-4276. http://dx.doi.org/10.1158/1078-0432.CCR-11-3114
8. Garin-Chesa, P., L.J. Old, and W.J. Rettig. 1990. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. Natl. Acad. Sci. USA. 87:7235-7239. http://dx.doi.org/10.1073/pnas.87.18.7235
9. Hofheinz, R.D., S.E. al-Batran, F. Hartmann, G. Hartung, D. Jäger, C. Renner, P. Tanswell, U. Kunz, A. Amelsberg, H. Kuthan, and G. Stehle. 2003. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie. 26:44-48. http://dx.doi.org/10.1159/000069863
10. Kelly, T., Y. Huang, A.E. Simms, and A. Mazur. 2012. Fibroblast activation protein-α: a key modulator of the microenvironment in multiple pathologies. Int Rev Cell Mol Biol. 297:83-116. http://dx.doi.org/10.1016/B978-0-12-394308-8.00003-0
11. Kraman, M., P.J. Bambrough, J.N. Arnold, E.W. Roberts, L. Magiera, J.O. Jones, A. Gopinathan, D.A. Tuveson, and D.T. Fearon. 2010. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 330:827-830. http://dx.doi.org/10.1126/science.1195300
12. Lee, J., M. Fassnacht, S. Nair, D. Boczkowski, and E. Gilboa. 2005. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res. 65:11156-11163. http://dx.doi.org/10.1158/0008-5472.CAN-05-2805
13. Liao, D., Y. Luo, D. Markowitz, R. Xiang, and R.A. Reisfeld. 2009. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS ONE. 4:e7965. http://dx.doi.org/10.1371/journal.pone.0007965
14. Loeffler, M., J.A. Krüger, A.G. Niethammer, and R.A. Reisfeld. 2006. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J. Clin. Invest. 116:1955-1962. http://dx.doi.org/10.1172/JCI26532
15. Méndez-Ferrer, S., T.V. Michurina, F. Ferraro, A.R. Mazloom, B.D. Macarthur, S.A. Lira, D.T. Scadden, A. Ma'ayan, G.N. Enikolopov, and P.S. Frenette. 2010. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 466:829-834. http://dx.doi.org/10.1038/nature09262
16. Mishra, P.J., P.J. Mishra, R. Humeniuk, D.J. Medina, G. Alexe, J.P. Mesirov, S. Ganesan, J.W. Glod, and D. Banerjee. 2008. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. 68:4331-4339. http://dx.doi.org/10.1158/0008-5472.CAN-08-0943
17. Morikawa, S., Y. Mabuchi, Y. Kubota, Y. Nagai, K. Niibe, E. Hiratsu, S. Suzuki, C. Miyauchi-Hara, N. Nagoshi, T. Sunabori, et al. 2009. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J. Exp. Med. 206:2483-2496. http://dx.doi.org/10.1084/jem.20091046
18. Narra, K., S.R. Mullins, H.O. Lee, B. Strzemkowski-Brun, K. Magalong, V.J. Christiansen, P.A. McKee, B. Egleston, S.J. Cohen, L.M. Weiner, et al. 2007. Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol. Ther. 6:1691-1699. http://dx.doi.org/10.4161/cbt.6.11.4874
19. Nombela-Arrieta, C., J. Ritz, and L.E. Silberstein. 2011. The elusive nature and function of mesenchymal stem cells. Nat. Rev. Mol. Cell Biol. 12:126-131. http://dx.doi.org/10.1038/nrm3049
20. Ostermann, E., P. Garin-Chesa, K.H. Heider, M. Kalat, H. Lamche, C. Puri, D. Kerjaschki, W.J. Rettig, and G.R. Adolf. 2008. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin. Cancer Res. 14:4584-4592. http://dx.doi.org/10.1158/1078-0432.CCR-07-5211
21. Rettig, W.J., P. Garin-Chesa, H.R. Beresford, H.F. Oettgen, M.R. Melamed, and L.J. Old. 1988. Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc. Natl. Acad. Sci. USA. 85:3110-3114. http://dx.doi.org/10.1073/pnas.85.9.3110
22. Rosenberg, S.A. 2012. Raising the bar: the curative potential of human cancer immunotherapy. Sci. Transl. Med. 4:ps8. http://dx.doi.org/10.1126/scitranslmed.3003634
23. Sabatino, M., J. Ren, V. David-Ocampo, L. England, M. McGann, M. Tran, S.A. Kuznetsov, H. Khuu, A. Balakumaran, H.G. Klein, et al. 2012. The establishment of a bank of stored clinical bone marrow stromal cell products. J. Transl. Med. 10:23. http://dx.doi.org/10.1186/1479-5876-10-23
24. Sadelain, M., R. Brentjens, and I. Rivière. 2009. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 21:215-223. http://dx.doi.org/10.1016/j.coi.2009.02.009
25. Santos, A.M., J. Jung, N. Aziz, J.L. Kissil, and E. Puré. 2009. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J. Clin. Invest. 119:3613-3625. http://dx.doi.org/10.1172/JCI38988
26. Scott, A.M., G. Wiseman, S. Welt, A. Adjei, F.T. Lee, W. Hopkins, C.R. Divgi, L.H. Hanson, P. Mitchell, D.N. Gansen, et al. 2003. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res. 9: 1639-1647.
27. Tripathi, M., S. Billet, and N.A. Bhowmick. 2012. Understanding the role of stromal fibroblasts in cancer progression. Cell Adh Migr. 6:231-235. http://dx.doi.org/10.4161/cam.20419
28. Tripodo, C., S. Sangaletti, P.P. Piccaluga, S. Prakash, G. Franco, I. Borrello, A. Orazi, M.P. Colombo, and S.A. Pileri. 2011. The bone marrow stroma in hematological neoplasms-a guilty bystander. Nat Rev Clin Oncol. 8:456-466. http://dx.doi.org/10.1038/nrclinonc.2011.31
29. Welt, S., C.R. Divgi, A.M. Scott, P. Garin-Chesa, R.D. Finn, M. Graham, E.A. Carswell, A. Cohen, S.M. Larson, L.J. Old, et al. 1994. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J. Clin. Oncol. 12:1193-1203.
30. Wen, Y., C.T. Wang, T.T. Ma, Z.Y. Li, L.N. Zhou, B. Mu, F. Leng, H.S. Shi, Y.O. Li, and Y.Q. Wei. 2010. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci. 101:2325-2332. http://dx.doi.org/10.1111/j.1349-7006.2010.01695.x